Vascugel is a novel allogeneic cell therapy product that restores natural repair and regeneration pathways in the vasculature. The upcoming phase II studies are to evaluate the continued safety of Vascugel as well as benefit for the maintenance of vascular patency after creation of arteriovenous access graft and AV fistula, respectively, for patients undergoing dialysis for the treatment of end-stage renal disease.
Steve Bollinger, president of Pervasis Therapeutics, said, “We look forward not only to evaluating the further safety and efficacy of Vascugel in a broader study environment, but also to developing groundbreaking new methods for measuring efficacy for this entirely new class of vascular therapeutic.”